Login
$IPSC
$1.64 -$0.00 (0.18%) After hours

$IPSC SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and remains on track for IND submission in 4Q 2026; initi...

12 Nov 2026 10-Q
05 Nov 2026 Form 4: Carr Douglas, SVP Finance & Operations

Sold 266 shares ($404)

03 Nov 2026 144
02 Oct 2026 8-K: Regulation FD Disclosure; Other Events

CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research

15 Sep 2026 Form 4: Russotti Gregory, See Remarks

Sold 2,587 shares ($4.99K)

15 Sep 2026 Form 4: Carr Douglas, SVP Finance & Operations

Sold 1,658 shares ($3.2K)

15 Sep 2026 Form 4: Pfeiffenberger Brent, Director

Gave up 13,850 shares to cover exercise price or tax ($26.9K)

14 Sep 2026 144
14 Sep 2026 144
10 Sep 2026 Form 4: Truitt Joseph, Director

Granted 148,000 Stock Option (right to buy)

10 Sep 2026 Form 3: Truitt Joseph, Director

No securities owned

09 Sep 2026 Form 4: Pfeiffenberger Brent, Director

Gave up 463 shares to cover exercise price or tax ($977)

09 Sep 2026 Form 4: Russotti Gregory, See Remarks

Sold 534 shares ($1.09K)

09 Sep 2026 Form 4: Carr Douglas, SVP Finance & Operations

Sold 254 shares ($521)

09 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1...

08 Sep 2026 144
18 Aug 2026 Form 4: Pfeiffenberger Brent, Director

Gave up 31,172 shares to cover exercise price or tax ($59.9K)

12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026

12 Aug 2026 10-Q

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support